Avanos Medical Q2 2024 Earnings Report

Avanos Medical EPS Results

• Actual EPS: $0.34
• Consensus EPS: $0.29
• Beat/Miss: Beat by +$0.05
• One Year Ago EPS: $0.24

Avanos Medical Revenue Results

• Actual Revenue: $171.70 million
• Expected Revenue: $170.67 million
• Beat/Miss: Beat by +$1.03 million
• YoY Revenue Growth: +1.40%

Avanos Medical Announcement Details

• Quarter: Q2 2024
• Date: 7/31/2024
• Time: Before Market Opens

Avanos Medical (NYSE:AVNS), a medical technology company, offers medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions. The company also provides a portfolio of non-opioid pain solutions, including surgical pain and recovery products, such as ON-Q and ambIT surgical pain pumps, Game Ready cold, and compression therapy systems. In addition, it offers interventional pain solutions, which offers minimally invasive pain-relieving therapies, such as Coolief pain relief therapy; OrthogenRx's knee osteoarthritis hyaluronic acid pain relief injection products; and Trident radiofrequency ablation products to treat chronic pain conditions. It markets its products directly to hospitals and other healthcare providers, healthcare facilities, and other end-user customers, as well as through third-party wholesale distributors. The company was formerly known as Halyard Health, Inc. and changed its name to Avanos Medical, Inc. in June 2018. Avanos Medical, Inc. was incorporated in 2014 and is headquartered in Alpharetta, Georgia.